John Quackenbush Leaves TIGR for Harvard, Carl Barrett Goes to Novartis Institutes from NCI, Ann Reynolds Joins Board of Invitrogen, and Others

John Quackenbush has been appointed professor of computational biology and bioinformatics jointly at the Harvard School of Public Health and at the Dana-Farber Cancer Institute, Harvard said earlier this month. He comes to Harvard from the Institute for Genomic Research, where he was an investigator. While at TIGR, he held appointments as professor of biochemistry at George Washington University and as adjunct professor of biostatistics at Johns Hopkins University.

Carl Barrett will become global head of oncology biomarkers at the Novartis Institutes for BioMedical Research in Cambridge, Mass.He used to lead the division of basic sciences and the center for cancer research at the National Cancer Institute.

Lester Crawford will be nominated as permanent head of the Food and Drug Administration, President Bush said on Monday. He is currently the agency's acting commissioner. Crawford, who was already considered for the position once before in 2001 but became deputy commissioner and acting commissioner instead, replaces Mark McClellan, who left the FDA in March of 2004 to become the head of the Center for Medicare and Medicaid Services. Crawford holds doctorate degrees in veterinary medicine from AuburnUniversity and in pharmacology from the Universityof Georgia.

Adrian Dillon has been promoted to executive vice president for finance and administration of Agilent Technologies, effective March 1, the company said on Monday. In addition to his current responsibilities for finance, planning and corporate development, information technology, and workplace services, he will take on new ones in global sourcing, Indiaoperations, corporate relations, customer financing, and contracts.

David Rutledge has been promoted to chief financial officer of the Southern Research Institute, SRI said last week. He has been with SRI for 19 years, serving as the company's controller for the last seven years. Rutledge holds a bachelor's degree in accounting from the University of Alabama at Birmingham.

Jean-Pierre Wery has become chief scientific officer and Lauri Caviston vice president of business development, sales, and marketing of the Indiana Centers for Applied Protein Sciences, INCAPS said last week.

Wery, who will replace interim CEO James Ludwig, joins INCAPS from Vitae Pharmaceuticals, where he was vice president of computational drug discovery. Prior to that, he held various positions at Eli Lilly.

Caviston previously held sales and marketing positions at BD Biosciences, CorningLife Sciences, and Roche Diagnostics Applied Sciences. She holds a BS from the Universityof Connecticut and a master's degree in biology from HarvardUniversity.

Christopher Southan will join the Universityof Nottinghamas visiting professor of proteomics in the department of biosciences. The honorary appointment is initially for three years. Southan is currently bioinformatics group leader in the molecular pharmacology department of AstraZeneca R&D in Möndal, Sweden. In the past, he held bioinformatics positions at Oxford GlycoSciences and Gemini Genomics.

Samraat Raha, former vice president of GE Healthcare's CodeLink microarray product line, has joined Agilent Technologies' life science and chemical analysis business unit as vice president of field operations for the Americas, according to BioCommerce Week, a GenomeWeb newsletter. Raha joined Amersham before the company's acquisition by General Electric and worked there for almost two years before joining Agilent. Previously, he was chief business officer for EraGen of Madison, Wis., and prior to that, he was vice president of discovery services and bioreagents for Incyte Genomics.

Sara Cunningham has been confirmed as CEO of Benitec, after becoming acting CEO following the resignation of John McKinley, the company said this month. She was also appointed to the company's board of directors. Before founding Avocel, an RNAi firm acquired by Benitec, Cunningham held positions at BD Biosciences and Clontech.

Martin Madaus has been appointed as chairman of the board of Millipore, effective March 1, the company said on Monday. He will replace Francis Lunger, the current chairman. Madaus has been Millipore's CEO and president since Jan. 1. Prior to that, he was responsible for Roche Diagnostics' North Americabusiness.

Ann Reynolds has joined the board of directors of Invitrogen, the company said on Monday. Until 2002, she was the president of the University of Alabama at Birmingham. Prior to that, she was the chancellor of the City University of New York, and before that, chancellor of the CaliforniaStateUniversitysystem. Reynolds holds a PhD and a master's degree in zoology from the Universityof Iowa, and a bachelor's degree in biology from Emporia State University in Kansas.

Jay Johnston and Gerard Vaillant have joined the board of directors of Luminex, the Austin, Texas-based company said last week. Laurence Hirsch and Thomas Caskey will retire from the board before the summer.

Johnstonis chairman of QuesTek Innovations. In the past, he was corporate vice president for diagnostic assays and systems at Abbott Laboratories. He holds an MBA in general management from Amos Tuck School of Business Administration and an AB degree in public administration from DartmouthCollege.

Until he retired last year, Vaillant was company group chairman of Johnson & Johnson He holds a master's degree and superior certificate in biochemistry and industrial chemistry from Paris University of Sciences and a degree in marketing from Ecole Superieure de Commerce de Paris.

David Danley has joined the board of directors of therapeutic antibody firm Hematech, the Sioux Falls, S.D.-based company said last week. He is the director for homeland security and defense programs at CombiMatrix. Prior to that, he was project manager of the chemical biological medical systems and joint vaccine acquisition program for the Department of Defense.

Celliance, a Serologicals subisidiary, has formed a "leadership team" that will be collectively responsible for managing day-to-day customer-focused operations and for implementing corporate objectives, Serologicals said last week. Team members are: Joe Kozma, vice president, sales; Craig Brown, vice president, controller; Rick Srigley, vice president, contract services; Chris Simonsen, vice president, research and development; Jim Kramer, acting vice president, operations; Diane Miller, executive director, human resources; Attilio Baldassi, director, marketing; and Wayne Vaz, director, business development  and strategic planning.

Joseph Fernandez, president of Active Motif, a Carlsbad, Calif., biotech firm specializing in cell and molecular biology research, has been named to the California Economic Strategy Panel. Fernandez formerly worked for Stratagene Cloning, Scripps Clinic, and Invitrogen.

Betty Woods has been named non-executive chairman of the board of directors for Beckman Coulter, effective April 7 at the company's stockholder's meeting. She will succeed John Wareham, who is retiring, the company said this month. Woods is the former president and CEO of Premera Blue Cross (formerly Blue Cross of Washington and Alaska) and chief executive officer of Premara, the holding company of Premera Blue Cross.

Harry Beaty and Frank Olson have reached Becton Dickinson's mandatory retirement age and have retired from BD's board of directors, according to a company SEC filing. Additionally, Basil Anderson, Gary Mecklenburg, James Perrella, and Alfred Sommer were elected to the board.

Stratagene amended its Sept. 1, 2002, employment agreement with John Pouk, senior vice president of global sales and international operations, the company said in an SEC filing. Stratagene terminated an option to purchase shares of common stock previously granted to Pouk, and changed his eligibility for a bonus that was previously determined. Beginning with the company's 2004 fiscal year, Pouk's annual performance bonus is subject to review by the board of directors and shall be determined and adjusted at the sole discretion of the board, the company said. He was granted a bonus of $42,123.64 for 2004. Additionally, Stratagene paid Joseph Sorge, its chairman, CEO, and president, a bonus of $90,000; Reginald Jones, senior vice president and chief financial officer, $65,000; Ronni Sherman, executive vice president and general counsel, $63,666.68; Nicolas Roelofs, former chief operating officer $57,260.83; Nelson Thune, senior vice president of operations, $45,924.24; and Mary Joanne Deal, Hycor senior vice president for marketing and sales, $40,952.

BayBio, a Northern Californialife science industry organization, has elected eight new directors and has added four members to its economic advisory board, the South San Francisco-based alliance said last week. The new directors are Corey Goodman of Renovis; Victoria Hale of the Institute for OneWorld Health; Steve James of KAI Pharmaceuticals; Joel Marcus of Alexandria Real Estate Equities; Phil Moody of Chiron; Alan Mendelson of Latham & Watkins; Kim Popovits of Genomic Health; and Dan Welch of InterMune. The new advisory board members are Neil Campbell of Mosaigen, Tim Garlick of Nasdaq, Elliot Parks of Ventana Global Funds, and Michael Schuppenhauer of Fleishman-Hillard.

Promoted? Changing jobs? GenomeWeb News wants to know. E-mail us at [email protected]to announce your move in PEOPLE, a weekly roundup of personnel changes in the genomics industry.